As of this week, it's become clear critics and activists have won their point. The FDA has announced Avandia and Actos will soon bear a "black-box" warning detailing possible cardiac failure risks faced by some patients. The warnings will also be placed on drugs which combine the drugs with another related medication, such as Avandamet, which includes both Avandia and Metformin.
The FDA has also recently released a review of reports of side effects from taking Avandia and Actos. The studies for significant weight gain and build of fluids, which can be warning signs for heart failure.
To learn more about the new warnings:
- read this Associated Press article [1] (reg. req.)
ALSO: What will the pharmas do with their army of Avandia salespersons now that demand has dropped? Article [2]
Related Articles:
FDA panel votes to keep Avandia on the market. Report [3]
Avandia risks exposed under deal to post data. Report [4]
Avandia controversy sparks FDA criticism. Report [5]
Glaxo: Avandia critic should pay for stock drop. Report [6]
Diabetes expert issued harsh Avandia critique in 2000. Report [7]
Links:
[1] http://www.boston.com/business/healthcare/articles/2007/08/15/diabetes_drugs_will_add_heart_risk_warnings/
[2] http://www.fiercebiotech.com/story/what-do-avandia-sales-force/2007-08-14
[3] http://www.fiercehealthcare.com/story/fda-panel-votes-keep-avandia-market/2007-07-31
[4] http://www.fiercebiotech.com/story/avandia-risks-exposed-under-deal-to-post-data/2007-05-23
[5] http://www.fiercehealthcare.com/story/avandia-controversy-sparks-fda-criticism/2007-05-24
[6] http://www.fiercehealthcare.com/story/glaxo-avandia-critic-should-pay-for-stock-drop/2007-06-07
[7] http://www.fiercebiotech.com/story/diabetes-expert-issued-harsh-avandia-critique-in-2000/2007-05-24